Precision-cut liver slices as an ex vivo model to evaluate antifibrotic therapies for liver fibrosis and cirrhosis
Responses to antifibrotic interventions can be detected and quantified with PCLS at the gene expression level. The antifibrotic effects of erlotinib are consistent between PCLS models of murine cirrhosis and those observed in vivo and in vitro. These results were verified in human cirrhotic PCLS. PCLS is an excellent model for assessing antifibrotic therapies that are aligned with the principles of replacement, reduction, and refinement (3Rs), and it will benefit preclinical and clinical research for human fibrosis and cirrhosis.
Authors
- Georg M. Lauer (ORCID: https://orcid.org/0000-0002-9792-4271)
- Motaz Qadan (ORCID: https://orcid.org/0000-0001-6951-8308)
- Raymond T. Chung (ORCID: https://orcid.org/0000-0003-1338-9564)
- Kenneth K. Tanabe (ORCID: https://orcid.org/0000-0003-1920-3417)
- Eliana T. Epstein (ORCID: https://orcid.org/0000-0001-5163-2399)
- Mozhdeh Sojoodi (ORCID: https://orcid.org/0000-0002-9946-5910)
- Michael Lanuti (ORCID: https://orcid.org/0000-0001-6049-1276)
- Bryan C. Fuchs (ORCID: https://orcid.org/0000-0002-2149-3081)
- Ben D. Leaker (ORCID: https://orcid.org/0000-0002-8503-7472)
- Ibrahim Ragab Eissa (ORCID: https://orcid.org/0000-0001-9454-6327)
- Yongtao Wang (ORCID: https://orcid.org/0000-0002-5640-4720)
- Guoliang Qiao
- J. D. Eddy (ORCID: https://orcid.org/0009-0004-2595-7578)
- Oizoshimoshiofu Dimowo
Institutions
- Harvard University (US)
- Massachusetts General Hospital (US)
- Massachusetts Institute of Technology (US)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1097/hc9.0000000000000558
- Citations
- 12
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.64
Funders
- Massachusetts General Hospital
- Broad Institute